These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 13679499

  • 1. Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis.
    Snanoudj R, Mamzer-Bruneel MF, Hermine O, Grunfeld JP, Chauveau D.
    Nephrol Dial Transplant; 2003 Oct; 18(10):2175-7. PubMed ID: 13679499
    [No Abstract] [Full Text] [Related]

  • 2. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [Abstract] [Full Text] [Related]

  • 3. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [Abstract] [Full Text] [Related]

  • 4. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [Abstract] [Full Text] [Related]

  • 5. Primary amyloidosis of the kidney.
    Shafique S, Wetmore J, Almehmi A.
    W V Med J; 2010 Feb; 106(1):22-4. PubMed ID: 20088306
    [Abstract] [Full Text] [Related]

  • 6. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
    Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC, Cha SS, Gertz MA.
    Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
    [Abstract] [Full Text] [Related]

  • 7. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL.
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [Abstract] [Full Text] [Related]

  • 8. Clinical and histological responses of renal amyloidosis to high-dose melphalan supported by autologous stem cell transplantation.
    Sanada S, Suzuki M, Shindo T, Suzuki S, Nakamichi T, Matsubara M, Maeda K.
    Nephrol Dial Transplant; 2008 Feb; 23(2):747-50. PubMed ID: 17989105
    [No Abstract] [Full Text] [Related]

  • 9. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T.
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [Abstract] [Full Text] [Related]

  • 10. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan.
    Kawai Y, Kinoshita K, Arai H, Kuwata A, Fukuoka Y, Yamaoka M, Imamura S, Tsutani H, Ueda T.
    Eur J Haematol; 2004 Jun; 72(6):448-50. PubMed ID: 15128426
    [Abstract] [Full Text] [Related]

  • 11. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
    Sanchorawala V, Seldin DC.
    Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
    [Abstract] [Full Text] [Related]

  • 12. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
    Breems DA, Sonneveld P, de Man RA, Leebeek FW.
    Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
    [Abstract] [Full Text] [Related]

  • 13. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
    Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI, British Society of Blood and Marrow Transplantation.
    Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
    [Abstract] [Full Text] [Related]

  • 14. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
    Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Tefferi A, Litzow MR.
    Bone Marrow Transplant; 2004 Dec; 34(12):1025-31. PubMed ID: 15516945
    [Abstract] [Full Text] [Related]

  • 15. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
    Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL, Falk RH, Skinner M.
    Ann Intern Med; 2001 May 01; 134(9 Pt 1):746-53. PubMed ID: 11329232
    [Abstract] [Full Text] [Related]

  • 16. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M, Immunopathology Group of the Italian Society of Nephrology.
    Nephrol Dial Transplant; 2008 Mar 01; 23(3):941-51. PubMed ID: 17951308
    [Abstract] [Full Text] [Related]

  • 17. Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation.
    Katoh N, Matsuda M, Yoshida T, Yazaki M, Morita H, Sakashita K, Ikeda S.
    Muscle Nerve; 2010 Jan 01; 41(1):138-43. PubMed ID: 19813189
    [Abstract] [Full Text] [Related]

  • 18. Nephrotic syndrome secondary to amyloidosis.
    Kneipp S, Himmelstein SB.
    Nurse Pract; 2000 Jun 01; 25(6 Pt 1):78, 81, 85-6 passim. PubMed ID: 10884998
    [Abstract] [Full Text] [Related]

  • 19. [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support].
    Schjesvold FH, Sjo M, Tangen JM, Hammerstrøm J, Brinch L.
    Tidsskr Nor Laegeforen; 2008 Jun 12; 128(12):1392-6. PubMed ID: 18552900
    [Abstract] [Full Text] [Related]

  • 20. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
    Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG.
    Bone Marrow Transplant; 2005 Oct 12; 36(7):597-600. PubMed ID: 16044137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.